Effect of fiberoptic bronchoscopic bronchoalveolar lavage with ambroxol on the SIRS and target organ damage in patients with severe pneumonia complicated by respiratory failure

• Main Authors: Xiao-Jun Deng, Li-Ping Yang
• Format: Article
• Language: English
• Published: Editorial Board of Journal of Hainan Medical University 2017-07-01
• Series: Journal of Hainan Medical University
• Subjects: Severe pneumonia; Respiratory failure; Bronchoalveolar lavage; Inflammatory response
• Online Access: http://www.hnykdxxb.com/PDF/201714/3.pdf

Objective: To study the effect of fiberoptic bronchoscopic bronchoalveolar lavage with ambroxol on the systemic inflammatory response syndrome (SIRS) and target organ damage in patients with severe pneumonia complicated by respiratory failure. Methods: A total of 68 patients with severe pneumonia complicated by respiratory failure who received inpatient treatment in our hospital between July 2013 and December 2016 were collected and then divided into the control group (n=35) who received conventional therapy and the observation group (n=33) who received fiberoptic bronchoscopic bronchoalveolar lavage with ambroxol + conventional therapy after the therapies were reviewed. The systemic inflammatory response as well as cardiac and liver function before and after treatment were compared between two groups of patients. Results: Before treatment, differences in serum levels of inflammatory factors, myocardial enzyme spectrum and liver function indexes were not statistically significant between the two groups of patients. After treatment, serum inflammatory factors IL-6, IL-8, TNF-毩 and CRP levels in observation group were lower than those in control group; serum myocardial enzyme spectrum LDH, α-HBDH, CKMB and cTnI levels were lower than those in control group; serum liver function index Alb content was higher than that in control group while ALP, TBA, ALT and AST contents were lower than those in control group. Conclusion: Fiberoptic bronchoscopic bronchoalveolar lavage with ambroxol can effectively reduce the degree of SIRS, and also reduce the cardiac and liver function injury in patients with severe pneumonia complicated by respiratory failure.